If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Regulatory News (IMM)

Share Price Information for Immupharma (IMM)

Share Price is delayed by 15 minutes
Get Live Data
3.745    0.00 (0.00%)
Bid:
3.60
Ask:
3.995
Spread: 0.395 (10.972%)
Market Cap: £23.37m
IMM Live PriceLast checked at - London Stock Exchange

Intraday Immupharma Share Chart

Directorate Change

30 Sep 2015 07:05

RNS Number : 6273A
Immupharma PLC
30 September 2015
 

 

FOR IMMEDIATE RELEASE

30 SEPTEMBER 2015

 

 

 

TIM MCCARTHY APPOINTED AS NON-EXECUTIVE CHAIRMAN

 

ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, is pleased to announce the appointment of Tim McCarthy as Non-executive Chairman, with immediate effect.

 

Mr McCarthy has a 35 year international business career in high growth biotech, healthcare and technology companies. He is currently Chairman and Non-Executive Director for a number of biotech and healthcare related companies, including Incanthera, Harvard Healthcare and Expedeon Holdings. Mr McCarthy is also the former Chief Executive Officer and Finance Director of a number UK listed public and private companies, including Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, Mr McCarthy has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

 

A Fellow of the Association of Chartered Certified Accountants, Mr McCarthy has an MBA from Cranfield School of Management.

 

 

Commenting on Tim McCarthy's appointment, Dimitri Dimitrou, Chief Executive Officer, said:

 

"We are delighted to have Tim join ImmuPharma as Chairman. This appointment represents a further strong addition to the Board. Tim's commercial and industry background together with capital markets experience will be extremely valuable as ImmuPharma progresses its lead compound, LupuzorTM, through its pivotal Phase III trial, as well as providing guidance on ImmuPharma's long term business strategy."

 

 

Current Directorships

Ark Analytics Solutions Limited

BBN International Limited

Dropped Limited

Expedeon Holdings Limited

Frangipani Dreams Limited

Harvard Healthcare Limited

Incanthera Limited

Spear Therapeutics Limited

Unnamed Limited

Wise Old Owl Limited

 

Directorships in the Last 5 years

Retail Service Team Limited*

 

\* This company entered into a Creditors Voluntary Winding-up on 12th December 2013, 8 months after Mr McCarthy's resignation of directorship. It was dissolved on 4 June 2015.

 

 

 

There are no other disclosures required in relation to Rule 17 or paragraph (g) of Schedule 2 of the AIM Rules for Companies.

 

For further information please contact:

 

ImmuPharma plc

+ 44 (0) 20 7152 4080

Dimitri Dimitriou, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+ 44 (0) 7721 413 496

Panmure, Gordon & Co., NOMAD & Broker

+ 44 (0) 20 7886 2500

Fred Walsh, Duncan Monteith, Corporate Finance

Charles Leigh-Pemberton, Corporate Broking

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
BOAPKCDNOBKDNCB
Date   Source Headline
2nd Jun 20165:26 pmRNSDirector/PDMR Shareholding
31st May 201610:38 amRNSHolding(s) in Company
26th May 20162:00 pmRNSResult of AGM
25th May 20167:00 amRNSHolding(s) in Company
4th May 20167:01 amRNSAnnual Financial Report & Notice of AGM
4th May 20167:00 amRNSFinal Results
26th Apr 20167:00 amRNSNotice of Results
22nd Apr 20169:50 amRNSHolding(s) in Company
9th Mar 20167:00 amRNSFirst European Site Opens - Patient Recruitment
8th Mar 201611:10 amRNSHolding(s) in Company
7th Mar 20163:31 pmRNSHolding(s) in Company
1st Mar 20167:00 amRNSEIS and VCT Qualifying Status and Issue of Equity
29th Feb 20168:02 amRNSHolding(s) in Company
24th Feb 201612:35 pmRNSIssue of Equity
22nd Feb 20161:39 pmRNSResult of GM
15th Feb 20167:00 amRNSUS PATIENTS COMMENCE DOSING IN PHASE III STUDY
5th Feb 201612:22 pmRNSPlacing and Subscription Raises £8.3 million
5th Feb 20167:00 amRNSProposed Placing and Subscription
21st Jan 20165:33 pmRNSHolding(s) in Company
15th Dec 20157:00 amRNSImmuPharma & Simbec-Orion - Investigators Meeting
7th Dec 20157:00 amRNSUpdate on the progress of Lupuzor
30th Nov 201511:55 amRNSHolding(s) in Company
4th Nov 20158:26 amRNSLupuzor Phase III Pivotal Trial Update
4th Nov 20157:00 amRNSLupuzor Phase III Pivotal Trial Update
23rd Oct 20157:00 amRNSDirectorate Change
30th Sep 20157:05 amRNSDirectorate Change
30th Sep 20157:00 amRNSInterim Results
29th Jul 20157:00 amRNSRichard Warr
27th Jul 20157:00 amRNSTERM SHEET SIGNED $14 MILLION FUNDING FOR LUPUZOR
25th Jun 20157:00 amRNSLupuzor's Founder Dr Slyviane Muller Awarded Medal
29th May 201512:50 pmRNSResult of AGM
6th May 20153:44 pmRNSAnnual Report & Accounts
6th May 20157:02 amRNSInterim Board Change
30th Apr 20157:05 amRNSDirectorate Change
30th Apr 20157:00 amRNSPreliminary Results
11th Feb 201512:02 pmRNSCANCER UPDATE: IPP-204106
27th Jan 20157:00 amRNSEnterprise Investment Scheme Status
22nd Jan 20157:00 amRNSCollaboration Agreement with Simbec-Orion
30th Oct 201411:10 amRNSHolding(s) in Company
28th Oct 20147:00 amRNSHolding(s) in Company
21st Oct 20147:00 amRNSAdditional Listing - Conditional Placing
20th Oct 20147:00 amRNSImmuPharma awarded EUR400,000 Grant
30th Sep 20147:05 amRNSHalf Yearly Report
30th Sep 20147:00 amRNSLupuzorT Gears Up To Start Pivotal Phase III trial
27th Jun 20141:11 pmRNSResult of AGM
27th Jun 20147:00 amRNSAccess to pioneering research in Bordeaux France
16th Jun 20147:00 amRNSNEW NUCANT PATENTS
23rd May 20147:00 amRNSAnnual Financial Report
21st May 20147:00 amRNSPreliminary Results
6th May 201412:47 pmRNSDr. Sylviane Muller - Presentation Abstract

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.